Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma 6Solid Tumor 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Mesothelioma, Malignant 4Advanced Solid Tumors 4Solid Tumors 3Stomach Neoplasms 2Solid Tumor, Adult 2Lung Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thymus Neoplasms 1Thymoma 1Select Advanced Solid Tumors 1Sarcoma 1Relapsed Pediatric Solid Tumor 1Neuroendocrine Tumors 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Microsatellite Instability 1Mesothelin-positive Advanced Refractory Solid Tumors 1Mesothelin-positive Advanced Malignant Solid Tumors 1KRAS G12V 1

Interventions

fludarabine 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Positive Advanced Solid Tumors × fludarabine × Other solid neoplasm × Clear all
NCT05681650 2023-12-12

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
30 enrolled
Other solid neoplasm

HER2 Positive Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡